- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MoAb firm Cytogen to acquire Cellcor
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells
Monoclonal antibody developer Cytogen of Princeton, NJ, has signeda definitive agreement to acquire Cellcor, a biotechnology firmbased in Newton, MA, that is developing a technique called autolymphocytetherapy (ALT), which uses a patient's immune cells to treat cancerand infectious diseases. Cellcor's first product, for treatingrenal cell carcinoma, is in phase III clinical studies.
The transaction will be handled through a stock swap, withCellcor shareholders receiving 0.6 shares of Cytogen stock foreach of the 5.5 million shares of Cellcor common stock. The dealwas valued at $19.5 million by analysts, who said Cellcor wasdown to its last month of cash.
In other Cytogen news, the company filed a new drug application(NDA) with the Food and Drug Administration for Quadramet, a samarium-153-basedagent for the treatment of pain due to cancer that has spreadto the bone. Cytogen has licensed U.S. marketing and manufacturingrights for Quadramet to Du Pont Merck.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
